Back to top
more

Addus HomeCare (ADUS)

(Real Time Quote from BATS)

$128.81 USD

128.81
49,591

+0.09 (0.07%)

Updated Oct 2, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (49 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson

The Zacks Analyst Blog Highlights: Tandem Diabetes Care, Addus HomeCare, Tailored Brands, Tellurian and Johnson & Johnson

    Tirthankar Chakraborty headshot

    Wall Street Brushes Off Trade War Fears: Top 5 Gainers

    The Dow climbed more than 700 points after investors downplayed fears over tariffs announced by both China and the United States.

      Is Addus HomeCare (ADUS) Stock a Solid Choice Right Now?

      Addus HomeCare (ADUS) could be an interesting play for investors as it is seeing solid earnings estimate revision in addition to having a robust industry rank.

        Addus HomeCare (ADUS) Shares March Higher, Can It Continue?

        As of late, it has definitely been a great time to be an investor in Addus HomeCare Corporation (ADUS).

          New Strong Sell Stocks for December 5th

          Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

            New Strong Sell Stocks for November 16th

            Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

              The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners

              The Zacks Analyst Blog Highlights: Malibu Boats, Addus Homecare, Exelixis, Gran Tierra Energy and Delek Logisitcs Partners

                DaVita Banks on Acquisitions, Escalating Expenses a Concern

                On Jun 23, we issued an updated research report on Denver, CO-based DaVita HealthCare Partners Inc. (DVA).

                  Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment

                  Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment

                    Avoid Market Volatility with 5 Low-Beta Stocks

                    In this article, we present a strategy which proves that low risky securities can also reap rewards if some specific parameters are considered.

                      Zacks.com featured highlights: Summer Infant, TerraVia Holdings, Addus HomeCare,Schnitzer Steel Industries and Research Frontiers

                      Zacks.com featured highlights: Summer Infant, TerraVia Holdings, Addus HomeCare,Schnitzer Steel Industries and Research Frontiers

                        Tirthankar Chakraborty headshot

                        New Strong Buy Stocks for May 23rd

                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                          Use Rising P/E Tactic to Find Out 5 Winning Stocks

                          Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.

                            Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

                            Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.

                              HealthSouth Corp (HLS) Looks Good: Stock Moves 8% Higher

                              HealthSouth Corporation (HLS) shares rose almost 8% in the last trading session.

                                Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y

                                Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20.

                                  Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

                                  Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.

                                    VIVUS to Regain Commercial Rights for Stendra from Sanofi

                                    VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.

                                      Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

                                      Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

                                        Allergan's Restasis Now Available in Multidose Bottle in U.S.

                                        Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

                                          Alexion (ALXN) Files for Soliris' Label Expansion in Japan

                                          Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).

                                            Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study

                                            Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.

                                              Keryx's Auryxia Added to Largest Medicare Part D Plan

                                              Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.

                                                Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down

                                                Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.

                                                  Jazz Sleep Disorder Drug Positive in Phase III Studies

                                                  Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.